World CDx Frankfurt - Companion Diagnostic Development / World CDx Frankfurt by Hanson Wade

Increase your likelihood of drug approval through effective CDx development

Lack of clinical relevance. That’s still the biggest challenge that limits the success of a CDx strategy. And it doesn’t matter who you partner with, or when, if your biomarker isn’t truly predictive.

2012 has seen huge progress in use of NGS, new bioinformatics tools, better models & greater access to clinical specimens. Accessing this knowledge now is vital to be able to better select and validate companion biomarkers.

World CDx Frankfurt brings together the leading minds to discuss these rapid advances and crucially, how you can use these approaches to increase confidence and speed in your CDx development. Featuring case studies from the largest and most successful Rx/Dx partnerships you can learn from their experiences and significantly reduce overall development time.

Discover how you can realise the CDx success you want in Europe and beyond, in just 2 days.

Optimise your CDx development practically and strategically

Improve biomarker discovery, validation and translation into the clinic, with real-world examples from Boehringer Ingelheim, Celgene and Geron
Utilise key insights from Shire and Astellas on the growing importance of sequencing and genomics in CDx development and what bioinformatic approaches are needed to support identification of truly predictive biomarkers
Uncover new stratification biomarkers being explored that will improve patient safety such as CTCs and cfDNA
Learn about the exploding applications of CDx outside of oncology. Hear case studies on approaches in AI, infectious disease, pain and metabolic disorders

Increase chances of approval by learning about the diverse European regulatory landscape

Streamline your regulatory approval process with practical solutions from industry experts including Alan Morrison, Vice President of Regulatory Affairs at Amgen and Magali Gibou, Senior Regulatory Affairs Manager at Transgene
Learn about the most effective reimbursement and market access strategies, and how to apply them to your own CDx projects. With advice from Novartis, NICE, and the European Centre for Public Health Genomics
Learn what your organisation can do to increase funding and improve alliances with Invest Dx, the most comprehensive overview of the CDx investment landscape and the first VC investment and partnering day focusing solely on CDx and personalised medicine

Find the perfect partner

The ideal balance of attendees from pharma and Dx, to enable the most effective business development conversations. With over 80% of attendees made up of C-level, Director and VP decision makers
A full and varied networking schedule, meaning you get to meet all the right people, in the ideal environment. With Speed Networking, highly interactive workshops, plus the opportunity to organise onsite 1-2-1 meetings with your potential partners. And of course the networking drinks reception at the end of Day 1
Practical information and real world case studies on how to partner effectively, from both sides of the commercial partnership, with perspectives from senior leaders at Almac, Roche and Novartis